-
Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies
•
Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings,…
-
SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round
•
China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million) in a Series C1 financing round, alongside “tens of millions” in bank loans. Investors included Guanzi Private Fund Management, Tian Rui Feng Nian, and Yixing Huarui. The proceeds will be used to support pre-clinical development,…
-
Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline
•
US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up…
-
Sophway Raises ‘Tens of Millions’ in Angel Round for Endoscope Development
•
Sophway Technology, a full HD endoscope system developer based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round. The round was led by Bioching Capital, with contributions from Vinno Capital and TusStar. The proceeds will be used to advance the domestic development of endoscope…
-
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
•
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co., Ltd to develop and commercialize two target products in mainland China. The collaboration involves a PDE4 inhibitor (target product one) and a protease inhibitor (target product two). Jumpcan will pay RMB 180 million (USD 24.8…
-
Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products
•
Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology and cellular technology specialist based in Zhejiang, has reportedly raised close to RMB 200 million (USD 27.5 million) in a Series B financing round. The round was led by Kequan Fund in the Anji County…
-
Yaguo Technology Secures Series A+ Funding for Airway Management Devices
•
Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The round was led by Weifang Zhongke Haichuang Equity Investment Partnership, with contributions from Beijing Jinke Huiyu Venture Capital Partnership. The…
-
Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round
•
Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised “tens of millions” of US dollars in another financing round. The round was led by Yuanbio Venture Capital, with participation from OrbiMed, Cenova Ventures, Lilly Asia Ventures, Gaorong Capital, Huihe Capital, and GC&H Investments. The…
-
Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of an equity transfer deal with OncoCare Medical Pte. Ltd. The decision follows the inability to fulfill all preconditions for the transaction within the agreed period. Deal OverviewIn June this year, Fosun Pharma had agreed to…
-
Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development
•
Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series D+ financing round, following a Series D financing round at the same scale in November 2021. The round was led by ZGC Science City and Beijing Innovation Industry Investment. The proceeds will be…
-
LEPU ScienTech Medical Technology Sets IPO Price Range Ahead of Hong Kong Listing
•
China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 22.46 million shares at a price range of HKD 29.15 (USD 3.71) to HKD 31.45 (USD 4.01) per share, potentially raising up…
-
ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs
•
China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a first batch of investors, including China Merchants China Direct Investments Ltd, Wuzhong Biomedical Industry Development Fund, and Qiandao Fund. The proceeds will be used to advance clinical studies of three product pipelines in the US…
-
ArieMedi Secures Series A+ Financing to Expand Precision Navigation Solutions
•
ArieMedi Medical Science, a leading precision navigation solutions provider based in Beijing, has announced the completion of its Series A+ financing round, raising “hundreds of millions” of renminbi. The funding was backed by Hairui Investment and Haier Capital. The proceeds will be allocated toward scientific research collaboration, clinical studies, technology…
-
ClinBrain Raises RMB 200 Million in Series C Financing to Boost Medical Big Data
•
Shanghai-based ClinBrain, a leading clinical data repository (CDR) and medical big data services provider, has reportedly secured RMB 200 million (USD 27.5 million) in a Series C financing round. The round was led by Legend Capital, with participation from the Shanghai Prosperity Fund. The company plans to use the funds…
-
Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion
•
China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to conduct an initial public offering (IPO) of 22.61 million shares on the Hong Kong Stock Exchange. The offering price is set to range from HKD 24.3 (USD 3.10) to HKD 27.7 (USD 3.53) per share.…
-
Gan & Lee Pharmaceuticals Plans RMB 814M Private Placement for Working Capital
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB 814 million (USD 111.4 million) through a private placement. The funds raised will be used as supplementary working capital to support the company’s operations and strategic initiatives. Shareholding Structure and Company ValuationMr. Gan Zhongru, the…
-
Venmedtech Raises Series B+ Funding for Iliac Vein Stent and Product R&D
•
Venmedtech, a Suzhou-based one-stop intravenous therapy product platform, has reportedly raised “tens of millions” of renminbi in a Series B+ financing round. The funding was contributed by Qiao Jing Capital and Zhuopu Venture Capital. Proceeds from the financing will be directed towards market promotion of the company’s Iliac vein stent…
-
Celgenyx Completes RMB 100M Series A Financing for Next-Gen Cell Therapy Development
•
China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A financing round, raising RMB 100 million (USD 13.68 million). The round was led by Vivo Capital. The proceeds will be directed toward the research and development of Celgenyx’s next-generation off-the-shelf cell therapy. Current Landscape of…
-
Easy-Flow Medical Secures Angel Funding for Peripheral Device Development
•
China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by Legend Capital, with participation from Shanghai Xinyue Jiupeng Enterprise Consulting Center. The proceeds will be allocated toward the research and development…
-
Zhejiang Pushkang Biotech Raises RMB 100M in Series C+ Financing
•
China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised over RMB 100 million (USD 13.7 million) in a Series C+ financing round. The round was led by Oct. Capital, with participation from Momentum Venture and Chang An Hui Tong, alongside returning investor Yinglian Health…
